申请人:JANSSEN PHARMACEUTICA NV
公开号:US20130245022A1
公开(公告)日:2013-09-19
Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
本文描述了某些含有杂环芳基取代的哌啶基和哌嗪基脲化合物,这些化合物可用作FAAH抑制剂。这些化合物可以用于制备药物组合物和治疗由脂肪酸酰胺水解酶(FAAH)活性介导的疾病状态、疾病和症状的方法,例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松和运动障碍(例如多发性硬化症)。